Venture Funding Deals, December 2015
This article was originally published in Start Up
Executive Summary
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a monthly review of emerging In Vitro Diagnostic, Medical Device, and Pharmaceutical companies that have received venture funding. This month’s column covers deals announced October through November 2015.
You may also be interested in...
Deals In Depth: October 2020
Two-year-old Insitro penned a potential $2.07bn collaboration with Bristol Myers Squibb focused on the discovery and development of therapies for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The start-up will apply its ISH platform to create induced pluripotent stem cell-derived disease models. BMS also announced a definitive agreement to acquire MyoKardia for $13.1bn in cash. Financing reached $10.4bn in biopharma, $1.4bn in device, and $1.7bn in diagnostics.
Dealmaking: Q3 Roundup Shows Deal Values Jump From Prior Quarter
Device company M&A values reached $17.9bn in Q3, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $8.2bn.
Financing: Q3 Roundup Shows Fall In Device Company Activity But A Rise In IVDs
During the third quarter, device company fundraising totaled $3.3bn; while in vitro diagnostic firms and research tools players raised $3.4bn.
Need a specific report? 1000+ reports available
Buy Reports